Video

Dr. Eggener on active surveillance: “There’s superb long-term outcomes”

"It’s an important topic to debate,” says Scott E. Eggener, MD.

In this video, Scott Eggener, MD, discusses the key points of the debate, “What is the Preferred Approach for Low Risk Prostate Cancer?” being presented today at the 2021 Society of Urologic Oncology Annual Meeting. Eggener is a Bruce and Beth White Family professor of surgery and radiology, vice chair of the section of urology, and director of the High Risk and Advanced Prostate Cancer Clinic at the University of Chicago Medical Center in Chicago, Illinois.

Related Videos
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Refining prostate cancer therapy strategy to address RAPTOR findings
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Soumyajit Roy, MS, MBBS: The effect of prostate cancer patient history in RAPTOR
 Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Nicholas van AS, MD, MBBCH: The case for SBRT as a standard of care for localized prostate cancer
Pierre Blanchard, MD, PhD: What can hydrogel space provide to optimal prostate cancer care?
Savita Dandapani, MD, PhD: Findings from the phase 2 SHARP trial
Related Content
© 2024 MJH Life Sciences

All rights reserved.